Eledon stock rises as ALS drug tegoprubart shows safety in mid-stage study
seekingalpha.com
finance
2022-05-31 10:56:04

gorodenkoff/iStock via Getty Images Eledon Pharmaceuticals (NASDAQ:ELDN) stock rose ~9% premarket May 31 after the company said tegoprubart met the main goals of safety and tolerability in a phase 2a trial of tegoprubart (formerly AT-1501) in patients with amyotrophic lateral sclerosis (ALS). ALS is progressive nervous system disorder which affects nerve cells in the brain and spinal cord, leading to loss of muscle control. The 12-week study ~ which included 54 patients with ALS at 13 treatment sites in the U.
